CR20220570A - Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas - Google Patents
Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismasInfo
- Publication number
- CR20220570A CR20220570A CR20220570A CR20220570A CR20220570A CR 20220570 A CR20220570 A CR 20220570A CR 20220570 A CR20220570 A CR 20220570A CR 20220570 A CR20220570 A CR 20220570A CR 20220570 A CR20220570 A CR 20220570A
- Authority
- CR
- Costa Rica
- Prior art keywords
- nanoparticles
- compositions
- making
- haf
- disorders
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
- 210000004381 amniotic fluid Anatomy 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Pregnancy & Childbirth (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
Abstract
En el presente documento, en ciertos aspectos, se presentan composiciones terapéuticas libres de células derivadas de líquido amniótico humano (HAF) y usos de las mismas para la prevención y el tratamiento de enfermedades y trastornos seleccionados
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063008355P | 2020-04-10 | 2020-04-10 | |
PCT/IB2021/052982 WO2021205411A1 (en) | 2020-04-10 | 2021-04-10 | Compositions comprising nanoparticles, method of making and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220570A true CR20220570A (es) | 2023-04-11 |
Family
ID=78007064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220570A CR20220570A (es) | 2020-04-10 | 2021-04-10 | Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas |
Country Status (14)
Country | Link |
---|---|
US (2) | US20210315939A1 (es) |
EP (1) | EP4132548A4 (es) |
JP (1) | JP2023515253A (es) |
KR (1) | KR20230022840A (es) |
CN (1) | CN115867298A (es) |
AU (1) | AU2021253889A1 (es) |
BR (1) | BR112022020441A2 (es) |
CA (1) | CA3179925A1 (es) |
CO (1) | CO2022015966A2 (es) |
CR (1) | CR20220570A (es) |
EC (1) | ECSP22086300A (es) |
IL (1) | IL297195A (es) |
MX (1) | MX2022012692A (es) |
WO (1) | WO2021205411A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230149471A1 (en) * | 2020-03-23 | 2023-05-18 | University Of Utah Research Foundation | Compositions and treatments for ischemic injuries |
CN115120615B (zh) * | 2022-06-10 | 2024-02-06 | 中国人民解放军海军军医大学 | miR-146a-5p过表达工程干细胞外泌体在制备治疗芥子气致肺损伤药物中的应用 |
US11980485B1 (en) * | 2022-12-28 | 2024-05-14 | Neumarker, Inc | Method and system for determining a treatment outcome prediction for a patient based on electroencephalograph |
US11771377B1 (en) * | 2022-12-28 | 2023-10-03 | Neumarker, Inc | Method and system for identifying cohorts of psychiatric disorder patients based on electroencephalograph |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013082487A1 (en) * | 2011-11-30 | 2013-06-06 | Children's Hospital Los Angeles | Afsc based therapies |
MA45272A (fr) * | 2015-06-27 | 2018-05-02 | Stimlabs Llc | Produits issus de liquide amniotique et procédés d'utilisation |
US9907821B2 (en) * | 2015-10-09 | 2018-03-06 | MAM Holdings of West Florida, L.L.C. | Amniotic fluid formulation for treatment of joint pain or disorders |
JP2019513136A (ja) * | 2016-03-23 | 2019-05-23 | ミメディクス グループ インコーポレイテッド | 羊水による治療の組成物及び方法 |
US10555973B2 (en) * | 2017-03-06 | 2020-02-11 | University Of Utah Research Foundation | Therapeutic compositions |
WO2019040790A1 (en) * | 2017-08-23 | 2019-02-28 | Merakris Therapeutics, Llc | COMPOSITIONS CONTAINING AMNIOTIC COMPONENTS AND METHODS FOR THEIR PREPARATION AND USE |
-
2021
- 2021-04-09 US US17/226,587 patent/US20210315939A1/en active Pending
- 2021-04-10 MX MX2022012692A patent/MX2022012692A/es unknown
- 2021-04-10 IL IL297195A patent/IL297195A/en unknown
- 2021-04-10 JP JP2022562119A patent/JP2023515253A/ja active Pending
- 2021-04-10 CN CN202180041860.8A patent/CN115867298A/zh active Pending
- 2021-04-10 AU AU2021253889A patent/AU2021253889A1/en active Pending
- 2021-04-10 BR BR112022020441A patent/BR112022020441A2/pt not_active Application Discontinuation
- 2021-04-10 CA CA3179925A patent/CA3179925A1/en active Pending
- 2021-04-10 WO PCT/IB2021/052982 patent/WO2021205411A1/en active Application Filing
- 2021-04-10 EP EP21784900.9A patent/EP4132548A4/en active Pending
- 2021-04-10 KR KR1020227039360A patent/KR20230022840A/ko unknown
- 2021-04-10 CR CR20220570A patent/CR20220570A/es unknown
-
2022
- 2022-11-08 CO CONC2022/0015966A patent/CO2022015966A2/es unknown
- 2022-11-09 EC ECSENADI202286300A patent/ECSP22086300A/es unknown
- 2022-11-18 US US17/990,522 patent/US20230092673A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ECSP22086300A (es) | 2023-02-28 |
WO2021205411A1 (en) | 2021-10-14 |
BR112022020441A2 (pt) | 2022-12-20 |
IL297195A (en) | 2022-12-01 |
AU2021253889A1 (en) | 2022-11-17 |
CN115867298A (zh) | 2023-03-28 |
JP2023515253A (ja) | 2023-04-12 |
EP4132548A4 (en) | 2024-05-22 |
CO2022015966A2 (es) | 2023-02-16 |
US20230092673A1 (en) | 2023-03-23 |
CA3179925A1 (en) | 2021-10-14 |
MX2022012692A (es) | 2023-03-08 |
KR20230022840A (ko) | 2023-02-16 |
US20210315939A1 (en) | 2021-10-14 |
EP4132548A1 (en) | 2023-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022012692A (es) | Composiciones que comprenden nanoparticulas, metodo de elaboracion y usos de las mismas. | |
MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
PH12020551572A1 (en) | Heterocyclic compounds as immunomodulators | |
JOP20220179A1 (ar) | N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها | |
PH12020551425A1 (en) | Rimegepant for cgrp related disorders | |
MX2019004549A (es) | Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos. | |
MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
MX2021011723A (es) | Ligandos de pseudocinasa tyk2. | |
MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
EP4233913A3 (en) | Improved bromocriptine formulations | |
MX2022009762A (es) | Moduladores del purinorreceptor 3 p2x (p2x3). | |
MX2022005563A (es) | Ligandos de la pseudoquinasa tyk2. | |
MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
ZA202204938B (en) | Enhancement and stabilisation of proteolytic activity of proteases | |
MX2022011576A (es) | Moduladores de nlrp3. | |
MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
EP4252776A3 (en) | Compositions and methods for treating ocular diseases | |
MX2019007041A (es) | Metodos y composiciones para tratar la enfermedad de parkinson. | |
WO2018140792A3 (en) | Neurotrophin mutants for treating hearing loss and other otic disorders | |
WO2021041324A3 (en) | Compositions and methods for the treatment of pathological pain and itch | |
MX2021008941A (es) | Moduladores gpr35. | |
MX2022012404A (es) | Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas. | |
WO2019014322A8 (en) | KINASE INHIBITORS FOR THE TREATMENT OF DISEASES | |
MX2023006076A (es) | Derivados de cannabinoides y su uso en el tratamiento de la inflamación y/o el dolor y/o la obesidad. |